Replimune Group, Inc. 13D

Baker Bros. Advisors LP and affiliates own about 11.8% of Replimune Group, Inc. and recently increased their position via a ~$33 million prefunded warrant purchase, stating investment purposes and general flexibility but no specific activist agenda currently.

Baker Bros. Advisors LP, together with its affiliated entities and principals Julian and Felix Baker, filed Amendment No. 1 to its Schedule 13D on Replimune Group, Inc., reporting beneficial ownership of approximately 11.8% of the company’s common stock (including pre-funded warrants and options) and disclosing participation in the issuer’s August 2026 equity offering through the purchase of 2,736,340 new $0.0001 pre-funded warrants for about $33 million; the investment is described as for general investment purposes, with flexibility to buy or sell securities and hold discussions with management and other investors, but without any specific activist plans or proposals at this time.

Filing Facts

CIK

1737953

Ticker

REPL

Form

13D

Source Type

fda

Accession

0001104659-26-094196

Alert Tier

7